Warner Chilcott (WCRX)
News
| Jun 01 | IV30(TM) GAINER $YUM +39.8% $DFS +31.19% $CTL +31.08% $WFC +25.3% $WCRX +24.29% $AXP +24.12% $USB +22.25% $FITB +22.2% $LEN +20.33% by livevol_pro |
| Jun 01 | IV30(TM) GAINER $YUM +30.92% $DFS +25.22% $WCRX +24.5% $NLY +23.01% $LEN +21.82% $CTL +20.57% $AXP +20.22% $WFC +18.2% $USB +16.77% by livevol_pro |
| Jun 01 | HIGH $PUT VOLU $TYC 2061% $EDU 1779% $IGT 898% $WCRX 633% $HCBK 629% $KEY 618% $CBG 615% $TKR 511% $SLE 475% $CXW 389% by livevol_pro |
| Jun 01 | IV30(TM) GAINER $DFS +26.35% $WCRX +24.33% $YUM +23.62% $LEN +19.86% $WFC +18.02% $AXP +17.11% $BBT +16.94% $USO +15.44% $A +14.71% by livevol_pro |
| May 30 | Merck, Pfizer Back Lawmakers Who Oppose Company Products |
| May 30 | $WCRX looks over-sold under market influence - still holding for a buy out here by RickPalmer907 |
| May 30 | $WCRX Currently there are 14 analysts that rate Warner Chilcott a buy, no analysts rate it a sell, and four rate it a hold. by RickPalmer907 |
| May 30 | Call selling targets Warner Chilcott |
| May 29 | $WCRX good reminder..I'm the vol on the July 15's by ITradeforMe |
| May 29 | $WCRX got me some.. thanks.. by markf |
| May 25 | Barclays on U.S. Specialty Pharmaceuticals: Model Updates on FRX, MRX, WCRX & PCRX Street Insider |
| May 24 | Warner Chilcott PLC (WCRX): Today's Featured Health Care Loser |
| May 23 | WCRX, Watson Pharma in Legal Tussle |
Profile
Exchange: NASDAQGS Sector: Healthcare Industry: Drug Manufacturers - Other
Warner Chilcott is a global specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the U.S. and Western European pharmaceuticals markets. Since being spun out of Warner-Lambert in 1996, Warner Chilcott has evolved, through a series of acquisitions and divestitures, from a small seller of undifferentiated products to a fully integrated pharmaceutical company with a broad portfolio of leading branded products. The acquisition of The Procter & Gamble Company's global branded pharmaceuticals business on October 30, 2009 transformed Warner Chilcott into a global pharmaceuticals company with significant scale and geographic reach. Headquartered in Dublin, Ireland, Warner Chilcott has employees in 12 countries in North America and Western Europe. The Company's manufacturing facilities are located in Puerto Rico, Northern Ireland and Germany. The company was founded in 1968.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Warner Chilcott is down 22.53% over the last year vs S&P 500 Total Return down 0.60%, Forest Laboratories down 3.60%, and ISTA Pharmaceuticals up 5.70%.
- WCRX Total Returns
- ^SPXTR Total Returns
- FRX Total Returns
- ISTA Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these WCRX related companies
Pro Strategies Featuring WCRX
Did Warner Chilcott make it into our Pro Portfolio Strategies?
WCRX Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other WCRX Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| WCRX | 18.05 | -0.81 | -4.29% | 4.501B |
| WCN | 30.52 | -0.43 | -1.39% | 3.761B |
| WCG | 53.85 | -2.62 | -4.64% | 2.307B |
| WCC | 55.79 | -3.70 | -6.22% | 2.425B |
| WCBOD | 18.32 | -0.48 | -2.55% | |
| WCBO | 18.32 | -0.48 | -2.55% | 353.94M |
| WBSN | 17.97 | -0.61 | -3.28% | 677.29M |
| XRM | 3.50 | -0.10 | -2.78% | 53.02M |
| XRIT | 5.54 | +0.00 | +0.00% | 477.05M |
| XRAY | 36.26 | -0.74 | -2.00% | 5.150B |
